Abnormal analyte preeclampsia: do the second-trimester maternal serum analytes help differentiate preeclampsia subtypes?

Objective:to determine if serum screen analytes identify preeclamptic patients at risk for small-for-gestational age newborns, maternal laboratory abnormalities and preterm delivery (<37 weeks gestation).study design:using a retrospective cohort of 102 preeclamptic patients, associations between serum screen analytes and newborn birth-weight percentile, gestational age (ga) at delivery and maternal pre-delivery laboratory abnormalities were evaluated using correlation coefficients and local polynomial regression.result:inhibin-a and maternal serum alpha fetoprotein were inversely correlated with newborn birth-weight percentile (−0.27, p=0.006; −0.35, p=0.00004) and delivery ga (r=−0.42, p<0.0001; r=−0.26, p=0.008) and positively correlated with pre-delivery aspartate aminotransferase (r=0.22, p=0.03; r=0.21, p=0.04) and lactate dehydrogenase (r=0.33, p=0.0007; r=0.29, p=0.004). a positive correlation was noted between both second-trimester beta human chorionic gonadotropin and estriol and maternal pre-delivery creatinine (0.28, p=0.004; 0.4, p<0.0001, respectively). hundred percent of patients with ⩾2 abnormal analytes delivered before 37 weeks gestation.conclusion:preeclamptic patients with abnormal serum screen analytes are more likely to have small-for-gestational age newborns, deliver preterm and have pre-delivery laboratory abnormalities.